Human Papillomavirus type distribution in invasive cervical cancer in Uganda

被引：31

作者：

Odida M. ^{[1
,2
]}

de Sanjosé S. ^{[3
]}

Quint W. ^{[4
]}

Bosch X.F. ^{[3
]}

Klaustermeier J. ^{[3
]}

Weiderpass E. ^{[2
,5
,6
,7
]}

机构：

[1] Department of Pathology, Faculty of Medicine, Makerere University, Kampala

[2] Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm

[3] Unit of Infections and Cancer, Catalan Institute of Oncology, Barcelona

[4] DDL Diagnostic Laboratory, Voorburg

[5] Department of Etiological Research, The Cancer Registry of Norway, Oslo

[6] Department of Genetic Epidemiology, Samfunded Folkhalsan, Helsinki

[7] Department of Community Medicine, Tromso University, Tromso

来源：

BMC Infectious Diseases | / 8卷 / 1期

关键词：

Cervical Cancer; Invasive Cervical Cancer; Multiple Infection; Cervical Cancer Case; Invasive Cervical Carcinoma;

D O I：

10.1186/1471-2334-8-85

中图分类号：

学科分类号：

摘要：

Background: We conducted a study aiming to describe Human Papillomavirus (HPV) type distribution in invasive cervical carcinoma in Uganda. Methods: 191 archival cervical carcinoma samples diagnosed in the Department of Pathology, Makerere University in Kampala between 1968 and 1992 were analysed using a sensitive PCR-Reverse Hybridization Line Probe Assay. Results: Out of the 186 cases of confirmed invasive cervical cancer in the study paraffin blocks, 114 were positive for HPV DNA. Specific HPV genotypes were identifiable in 109 cases: HPV 16, 18, 31, 35, 39, 44, 45, 51, 52 and 70. These occurred as single infections in 105 cases (96.3%) and as multiple infections in 4 cases (3.7%). HPV 16 or 18 accounted for 80% (84/105) of cases with single infection. Conclusion: The results of this study confirm the role of HPV 16 and 18 in cervical cancer pathogenesis in the Ugandan population. The results suggest that the currently available HPV vaccines against HPV 16 and 18 could possibly prevent the majority of invasive cervical cancers in Uganda. © 2008 Odida et al; licensee BioMed Central Ltd.

引用

共 36 条

[11]

Harper D.M., Franco E.L., Wheeler C.M., Moscicki A.B., Romanowski B., Roteli-Martins C.M., Jenkins D., Schuind A., Costa Clemens S.A., Dubin G., Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: Follow-up from a randomised control trial, Lancet, 367, pp. 1247-1255, (2006)

[12]

Mao C., Koutsky L.A., Ault K.A., Wheeler C.M., Brown D.R., Wiley D.J., Alvarez F.B., Bautista O.M., Jansen K.U., Barr E., Efficacy of human papillomavirus-16 vaccine to prevent cervical intraepithelial neoplasia: A randomized controlled trial, Obstet Gynecol, 107, pp. 18-27, (2006)

[13]

Villa L.L., Costa R.L., Petta C.A., Andrade R.P., Paavonen J., Iversen O.E., Olsson S.E., Hoye J., Steinwall M., Riis-Johannessen G., Andersson-Ellstrom A., Elfgren K., Krogh G., Lehtinen M., Malm C., Tamms G.M., Giacoletti K., Lupinacci L., Railkar R., Taddeo F.J., Bryan J., Esser M.T., Sings H.L., Saah A.J., Barr E., High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up, Br J Cancer, 95, pp. 145

[14]

Kleter B., van Doorn L.J., ter Schegget J., Schrauwen L., van Krimpen K., Burger M., ter Harmsel B., Quint W., Novel short-fragment PCR assay for highly sensitive broad-spectrum detection of anogenital human papillomaviruses, Am J Pathol, 153, pp. 1731-1739, (1998)

[15]

Rughooputh S., Eddoo R., Manraj S., Jeebun N., Greenwell P., Detection of human papillomavirus from archival tissues in cervical cancer patients in Mauritius, J Clin Virol, 35, pp. 173-178, (2006)

[16]

Bertelsen B.I., Kugarajh K., Skar R., Laerum O.D., HPV subtypes in cervical cancer biopsies between 1930 and 2004: Detection using general primer pair PCR and sequencing, Virchows Arch, 449, pp. 141-147, (2006)

[17]

Quint W., Brunsveld J.P., Klaustermeier J., de Sanjose S., Lloveras B., Font R., Sanchez G.I., Tous S., Molijn A., Munoz N., Bosch F.X., Search of the appropriate algorithm for the evaluation of HPV negative blocks of invasive cervical cancer, Book of Abstracts. 23rd International Papillomavirus Conference and Clinical Workshop, (2006)

[18]

Hammouda D., Munoz N., Herrero R., Arslan A., Bouhadef A., Oublil M., Djedeat B., Fontaniere B., Snijders P., Meijer C., Franceschi S., Cervical carcinoma in Algiers, Algeria: Human papillomavirus and lifestyle risk factors, Int J Cancer, 113, pp. 483-489, (2005)

[19]

Castellsague X., Klaustermeier J., Carrilho C., Albero G., Sacarlal J., Quint W., Kleter B., Lloveras B., Ismail M.R., de Sanjose S., Bosch F.X., Alonso P., Menendez C., Vaccine-related HPV genotypes in women with and without cervical cancer in Mozambique: Burden and potential for prevention, Int J Cancer, 122, pp. 1901-1904, (2008)

[20]

Munoz N., Bosch F.X., Castellsague X., Diaz M., de Sanjose S., Hammouda D., Viladiu P., Navarro C., Martos C., Ascunce N., Against which human papillomavirus types shall we vaccinate and screen? The international perspective, Int J Cancer, 111, pp. 278-285, (2004)

← 1 2 3 4 →